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Abstract:
Background: Buprenorphine‟s availability in primary care settings offers increased access
to treatment and linkage to primary care for opioid-dependent patients. Currently,
tuberculin skin testing (TST) is recommended for patients enrolling in methadone
maintenance treatment (MMT), but not for those enrolling in buprenorphine maintenance
treatment (BMT).
Objectives: To compare TST screening results in enrollees in BMT and MMT programs
and assess the correlates of TST positivity among these subjects.
Methods: A cross-sectional analysis of a retrospective cohort study was conducted to
compare concurrent TST results among contemporaneously matched groups of MMT and
BMT patients in the same community.
Results: TST positivity was 9% in both MMT and BMT settings (p = .27). Increased TST
positivity was associated with being Black (AOR = 3.53, CI = 1.28–9.77), Hispanic
(AOR = 3.11, CI = 1.12–8.60), and having higher education (AOR= 3.01, CI = 1.20–
7.53).
Conclusions: These results confirm a similarly high prevalence of TST positivity in
opioid-dependent patients enrolling in MMT and BMT programs. Racial and ethnic
health disparities remain associated with TST positivity, yet a relationship between
higher education and tuberculosis requires further investigation.
Scientific significance: These data suggest the importance of incorporating TST screening
in emerging BMT programs as a mechanism to provide increased detection and treatment
of tuberculosis infection in opioid-dependent patient populations
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Introduction
Substance Dependence
“Drug addiction,” or more formally “substance dependence” as termed by the American
Psychiatric Association, is defined as a “maladaptive pattern of substance use leading to
clinically significant impairment or distress, as manifested by three (or more) of the
following, occurring any time in the same 12-month period: tolerance; withdrawal;
increasing use (quantity and/or frequency) over time; persistent but unsuccessful
intention to cut down on use; significant time occupied by habit; social, occupational and
recreational activities suffer as a result; and/or usage is continued in spite of recognition
of deleterious physical or psychological effects [1].
In the United States today it is estimated that approximately 2 million (range between 1.5
and 2.4 million) people are dependent upon opiate-containing substances [2, 3]. In
addition to heroin, opioids of abuse range from natural opium to manufactured forms
including codeine, fentanyl, hydrocodone, methadone, morphine, and oxycodone.
Natural opium has been used recreationally for over five thousand years with Sumerian
records of a “joy plant” dating back to ancient Mesopotamia in 3400 B.C. [4]. Since the
Sumerians, opioids have been used continuously, both recreationally and clinically, in
cultures around the world. Opioids can be taken through intravenous, intranasal or
inhalation routes of administration and are regularly used for many clinical indications in
addition to their potential for abuse.
Of the approximate 2 million opiate-dependent persons in the United States presently,
approximately 900,000 are dependent on heroin [5]. Irrespective of the opiate or
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administrative route of choice, opiate dependence is a significant problem in the United
States today with enormous social and economic costs to society [6]. A National Institute
of Justice study reported that over 60% of inmates in federal prisons in 2002 were
incarcerated for crimes associated with illicit substances trade or usage [7]. In addition to
the challenges posed in the legal and social realms by substance abuse, the financial costs
are substantial: a 1994 study suggested that in New York City alone substance abuse cost
tax payers over 20 billion dollars [8]. Since 1994 the number of substance users has
increased, as has the cost. While the socioeconomic challenges associated with substance
dependence are notable, they are, however, outside the scope of this paper. In this report
we will discuss in greater detail specific concerns surrounding the implementation of
substance dependence treatment programs and the policy implications necessary to
optimize treatment for this marginalized population.

Health status of substance users
Substance dependence has significant impact on the health status of substance-dependent
patients, including higher rates of infectious diseases, medical comorbidities, and mental
illness [9-14].
Epidemiologically, individuals who use illicit substances, and particularly opioids, are at
increased age-matched risk for associated infectious diseases. For example, many studies
have shown substance users to have higher rates of human immunodeficiency virus
(HIV)[10, 15]. While many opioids are used by patients with HIV, those that are
injectable have contributed most to the transmission of HIV through needle-sharing
practices involving blood-to-blood contact [5]. Currently, over one in three cases of
HIV/AIDS in the United States are accounted for by injecting drug users (IDUs) or their
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partners or children, and approximately 25% of new HIV cases annually in the United
States are secondary to injecting drug use practices [10, 15]. In addition to high rates of
HIV/AIDS, higher rates of tuberculosis have also been documented in this population,
with both increased risk of Mycobacterium tuberculosis infection and tuberculosis
disease [11, 16]. Increased risk for tuberculosis is due in part to the fact that it is a
common opportunistic infection associated with HIV, and further that HIV markedly
increases reactivation of latent tuberculosis infections [17]. Higher rates of tuberculosis
are additionally caused by the impoverished and cramped living conditions many
substance users live in; such living quarters can increase the risk of air-borne
transmission of Mycobacterium tuberculosis causing infection and leading to disease
[11]. Similarly, other research has shown that rates of viral hepatitis are increased in
populations who use opioids through intravenous routes [12, 18]. There is a higher risk
for transmission of both hepatitis B and hepatitis C viruses through blood-to-blood
contact which frequently occurs through needle sharing in injecting drug use.
Additionally, many patients who contract one form of viral hepatitis via intravenous drug
abuse are co-infected with both hepatitis B and C, with some studies showing over 80%
co-infection rates in this population [19].
In addition to the increased risk of infectious diseases, this population is also
disproportionately affected by mental illness. Research demonstrates that mental
illnesses such as depression, schizophrenia and bipolar disorder are increased in this
population and can lead to higher risk-taking behavior, including substance use, injecting
drug use, and high-risk sexual practices that may expose persons to sexually transmitted
infections including HIV [13, 20].
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Marginalization from health services
This disparity in general health status amongst substance users, and specifically those
who use intravenous drugs, has been well documented yet remains largely unaddressed.
In part, poor health status is due to a significant marginalization of these individuals from
mainstream healthcare resources [21, 22]. This marginalization is multi-factorial,
however in part occurs due to stigma against substance users both from the general public
as well as health care providers [23, 24]. Despite significant evidence illustrating the
benefits of substance abuse treatment modalities such as methadone [25], many health
care practitioners continue to be uncomfortable treating active substance users. One study
of primary care practitioners in New York City treating HIV patients revealed 55% were
uncomfortable providing services to patients injecting drugs [26]. Other clinicians may
be comfortable working with substance users however are wary of long-term
maintenance treatment approaches (i.e. medication-assisted treatment – further discussed
below) [27]. In the latter case, while care may be provided, it is frequently sub-optimal
as the doctor-patient relationship is compromised by a lack of trust between parties and
discomfort on the part of the clinician in dealing with this population [28].
Whether clinicians do or do not provide services to this population, in both cases
practitioners often maintain that substance dependence is different from other diseases
and understand substance dependency as a personal choice, and accordingly not a
responsibility of the public health care system. The New York Academy of Medicine
discusses how, “…much of the general public and those in the health care field have
come to believe that drug dependence is essentially self-indulgent, voluntary behavior for
which individuals should take personal responsibility [28].” Consequently public opinion
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frequently maintains that substance dependence should be dealt with politically (i.e.
keeping illicit substances off the street) and/or legally (i.e. punishing those who
participate in the trade or use of such substances), but not medically. In parallel, there is
reticence amongst health care providers to offer treatment to substance users as
discussed. Furthermore, for some clinicians who do provide treatment to this population
there is a harsher approach to medication non-compliance given the view that substance
dependence is a fundamentally different type of disease than other chronic illnesses such
as diabetes or HIV [29-32].
These perceptions are in contrast to a significant body of literature which understands
substance dependence as a chronic illness influenced by biological, psychological and
socioeconomic factors, not unlike other chronic illnesses such as HIV or diabetes.
Multiple previous studies – including twin studies, cohort studies, and randomized
control trials – have lead science to now purport that substance dependence must be
conceptualized and treated as a non-curable, chronic disease. Twin studies have shown
that there is a significant genetic component to substance dependence [33-35].
Additionally, we now know that there are typical neurostructural and neurochemical
responses to substance use and dependence underlining the pathophysiologic nature of
dependence [36, 37]. Finally, we know that social problems such as poverty, poor social
support structures, or psychiatric co-morbidities portend a poor outcome of treatment
with frequent non-compliance to treatment plans and relapse following discharge [38,
39]. While none of this evidence is sufficient to state that substance dependence is by
definition a chronic illness, when held up against well-established literature of other
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chronic diseases such as asthma, hypertension, or diabetes, there is a striking similarity
between the etiology and correlates of treatment success [28].
More specifically, several key challenges exist in working with this population that
complicate the ability of clinicians to provide effective and/or compassionate care. Due to
an often chaotic set of life circumstances, many substance users have significant
difficulty interacting with the health care system in a traditional fashion. For instance,
many patients in this population have difficulty keeping set appointment times required at
most health facilities and therefore frequently utilize emergency departments or drop-in
clinics as a replacement for general primary care centers [40-43]. Secondly, high
psychiatric co-morbidities can make these patients challenging and often frustrating to
deal with [28]. The same mental illness burden also leads to challenges for such patients
in accessing reliable and consistent primary care [13]. Finally, there is a dearth of
effective medical and psychosocial outreach programs engaging this population to enter
treatment in the traditional fashion, further exacerbating the tendency of this population
to visit emergency departments with late-stage disease rather than accessing primary care
services on a regular basis [44].
However, aside from the multiple factors making this population less likely to regularly
access health resources, and irrespective of whether substance dependence should in fact
be examined through the lens of a chronic illness, current public opinion, including that
of many health care workers, has not yet adopted this perspective. This has lead to an
increasing and continued stigmatization of this population which has only exacerbated
the difficulty in effectively providing health services to such patients. In particular, it has
lead to a lack of primary care practitioners willing to provide services for these patients,
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and additionally has created an even greater perceived lack of health services given the
dearth of information readily available to this population.
Medication-assisted treatment
Medication-assisted treatment, or a therapeutic modality for substance dependence in
which medications are used in parallel with behavioral therapy, is the most effective
treatment strategy in this population [45, 46]. Furthermore, it is an important strategy to
address parallel and comorbid health issues for substance-dependent patients.
Medications such as methadone and buprenorphine – further described below – have
been shown to provide several key benefits to this population. Primarily, these
medications, especially when paired with behavioral therapeutic approaches are the most
effective modality to address substance dependence [45, 46]. Secondarily, medicationassisted treatment modalities have been demonstrated as effective means to engage
patients in treatment for associated conditions, including infectious diseases, mental
health, and/or non-substance-dependence related medical comorbidities. A third critical
benefit of medication-assisted treatment is that, in addition to acting as a foundation for
increased patient health services engagement, it enhances adherence to treatments for
associated conditions, including for instance, HIV and tuberculosis [45-48]. In this paper
we will primarily discuss the two most effective medication-assisted treatments,
methadone and buprenorphine.

Methadone: medication-assisted treatment for substance dependence
Methadone is a synthetic, full mu-opioid agonist, originally developed in 1939 in
Germany in an effort to identify alternative opiates due to a nation-wide opium shortage.
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In 1947 it was introduced in the United States by Eli Lily as an analgesic medication
under the name of Dolophine. Since then it has become more well-known for its ability
to treat opiate dependence when used as an opiate substitution therapy, or, a “medicationassisted treatment.” In 1964 Vincent Dole and Marie Nyswander of Rockefeller
University, first pioneered the use of methadone to treat heroin addiction. They initially
treated 22 patients using methadone and were able to successfully show that patients
treated with methadone in combination with psychosocial interventions stopped heroin
usage and regained self-confidence and an ability to live typical family and work lives
[49]. This study laid the foundation for the usage of methadone as a medication-assisted
treatment; Dole later received the Lasker award for this work.
Since the 1960s the usage of methadone for opiate dependence has become much more
well refined with methadone maintenance therapy now offered in outpatient settings
throughout the world [24, 25]. Methadone maintenance treatment is a medicationassisted treatment and therefore patients typically take methadone for long, if not
indefinite, periods of time following opiate dependence. In treatment programs patients
receive daily doses under the regular supervision of a certified doctor with doses ranging
significantly depending upon the individual. In the United States most programs initiate
patients on a low dose and gradually increase daily dosage until symptoms of withdrawal
and cravings for opiate use are well controlled. For most programs, patients are initially
required to visit a clinic daily to receive their treatment. However, following a certain
period of time – location and provider-dependent, and pending continued compliance and
negative drug screening tests – patients are allowed to visit the clinic less frequently,
taking some of their doses independently at home.
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With now over 40 years of research examining the impact of methadone maintenance
treatment there is evidence of multiple benefits resulting from treatment programs. First,
methadone can successfully manage opiate dependence, especially when paired with
additional psychosocial interventions [24, 25, 50]. Secondly, methadone programs have
been shown to be a cost-effective intervention when examining their impact on public
health as well as societal economic and financial statistics [51]. Methadone has also been
shown to have ancillary beneficial effects including: reducing rates of prison recidivism
[52]; decreasing transmission of infectious diseases including HIV, tuberculosis and viral
hepatitis [53]; improving clinical compliance and treatment outcomes for chronic
illnesses [30, 54]; enhancing general employment status and opportunities [55];
decreasing high-risk behaviors such as needle sharing and injecting [56] as well as
overdoses from opiate abuse [57]; and, generally improving psychological and physical
health status for patients enrolled in treatment programs [58].

Regulation of methadone treatment
Despite research demonstrating the marked benefits of methadone maintenance
treatment, however, it remains a controversial issue, and access to methadone treatment is
available in only a limited capacity due to stringent legal and clinical regulations for use.
A brief discussion of the history of regulations surrounding methadone and other opiatereplacement therapies is instructive to understanding the current policy debates
surrounding newer treatment modalities.
Prior to Dole and Nyswander‟s seminal work with methadone at Rockefeller in the early
1960s, prescribing opiates to opioid-dependent patients in the United States was difficult,
if not impossible. In 1914 the Harrison Act along with a group of passionate anti-opioid
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politicians began to limit the ability of clinicians to prescribe opiates to this population.
In 1920, when the American Medical Association similarly condemned the practice,
clinicians began to be formally prosecuted for offering opiate-replacement therapies.
During much of this period Harry Anslinger was head of the Bureau of Narcotics –
Ansligner purported that severe penalties for possession, use or sale of illicit substances
would ultimately eliminate substance dependence. Similarly, he was not in favor of
opiate-replacement therapies and lead efforts to stop clinicians from engaging in such
practices [32].
Data from the Rockefeller studies came out in the setting of a harsh legal environment for
substance users as well as the clinicians that aimed to treat them, however also at a time
when sentiment for the treatment and “rehabilitation” of opiate-dependent patients was
on the rise [59, 60]. Following Dole and Nyswander‟s data, multiple treatment centers
sprang up throughout the country functioning mainly through Investigational New Drug
(IND) certifications issued by the Food and Drug Administration. IND certification was
important as it allowed centers to provide treatment in spite of the Bureau of Narcotics
continued opinion that providing opiates to substance-dependent patients was illegal.
While thousands of patients were enrolled in treatment in the first 10 years [2],
government agencies maintained their opposition to the programs and many activist and
patients-rights groups derided the practice as an inappropriate approach to the treatment
of substance abuse [61]. During this time the FDA refused to qualify methadone as a
legitimate form of therapy, thereby limiting the number of programs functioning under
the label of “research.” These limitations quickly lead to many opiate-dependent patients
(largely heroin) being unable to enroll in treatment and generated long waiting lists for
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programs [32]. In 1973 new Federal regulations were approved, and while originally
intended to be revised regularly, between approval and 2001, were only amended twice.
Most notably in the 1973 revisions was included the implementation of a physician
accreditation process for the prescription of methadone. In 1974, Congress approved
further oversight mechanisms for methadone treatment programs, placing much of the
jurisdiction under the DEA [62].
Between the 1920s and 2003 the number of patients receiving methadone has increased
from approximately 20,000 to 180,000; still only a significant minority of the opiatedependent population in the United States. Throughout this time period efforts were
made to revise and ease the FDA regulations however significant resistance was voiced
by both the DEA as well as clinicians offering treatment [32]. Ultimately, while opinions
are diverse, the regulatory environment during the 1970s, 80s, and 90s has largely been
credited with limiting access to methadone treatment.

Buprenorphine – a new medication-assisted treatment
Buprenorphine is a partial-opiate agonist that was first noted to have potential clinical
utility in 1978 [63]. At the time, buprenorphine was particularly interesting due to its
potential to limit the adverse side effects associated with methadone toxicity in opiatenaïve individuals. Potential clinical use for substance dependence, and evidence for
limited toxicity, was formally illustrated by the early 1990s [64-66]. In addition to data
suggesting that buprenorphine could be an effective clinical treatment for opioiddependence, the limited toxicity (due to its partial agonist properties and formulation)
significantly decreased concerns for diversion of the medication as it largely limited the
potential for overdoses seen frequently with methadone. This lead many clinicians and
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scientists to believe that following FDA approval for the clinical use of buprenorphine, it
might be exempted from many of the severe regulatory constraints that limited
methadone treatment access.
Due in large part to the efforts of private pharmaceutical company Reckitt and Colman –
who decided to market buprenorphine and in doing so take on the legal and political
bureaucracy involved in the regulation of methadone – and accompanied by several key
political allies, legislation was developed to ease the previous regulations for opiatereplacement therapies. The political lobbying was done with the express intention of
establishing the legal framework necessary to expand the potential patient population for
buprenorphine prior to Reckitt and Colman bringing the drug to market. Beginning in
1995, the legislation of the proposed Drug Addiction Treatment Act (DATA) – a rather
minor amendment to the existing legislation – took more than 5 years to finally be passed
by Congress. In 2000, President Clinton signed into law the DATA which offered
clinicians the opportunity to obtain special training which would exempt them from
obtaining DEA certification as well as allow them to offer buprenorphine treatment
outside of federal methadone regulations [32].
On October 8th, 2002 buprenorphine was approved for the treatment of opiatedependence making it the third such drug to gain certification (LAAM – levo-alphaacetyl methadol, a similar compound to methadone – had been previously approved in
1993 by the FDA however was subsequently removed from both the European and US
markets in 2001 and 2003 respectively). Buprenorphine is a partial opioid agonist at the
mu-opioid receptor and an antagonist at the kappa-opioid receptor [63]. As a result,
buprenorphine blocks patients‟ ability to use exogenous opioids while at the same time
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preventing withdrawal symptoms. Similarly, buprenorphine has a lesser potential for
abuse or overdose and therefore risks of diversion are of less concern than those for
methadone [66]. Because of these pharmacological properties, buprenorphine has been
classified as a Schedule III medication whereas methadone is a Schedule II; this will
enable its wider use clinically and aid in eliminating stringent regulatory barriers seen
with methadone.
Previous research has shown that buprenorphine is an effective maintenance therapy in
multiple dosage formulations – including daily or several times weekly – and is
manufactured both singly as well as in a dual-formulation with naloxone to further
prevent diversion efforts [67]. Multiple previous studies have shown effect with
buprenorphine maintenance therapy in various settings including outpatient primary care
clinics [23, 68] and other research suggests its use as a cost-effective public health
measure [69].
Buprenorphine maintenance treatment involves three major phases – 1) induction, 2)
stabilization, and 3) maintenance. In the induction phase patients are given a “test dose”
which is typically observed at the treatment facility. This initial dose is usually 4mg and
is given after a patient has been opiate-free for 12 to 24 hours and beginning to
experience symptoms of opiate withdrawal. Following verification that the patient
tolerates the initial test dose, dose titration is begun rapidly to a dose of 16mg typically
by day number two. At this point the stabilization phase begins during which time the
patient works with their clinician to achieve a dose at which they can greatly reduce or
cease entirely opiate usage. Psychosocial counseling and behavioral interventions are an
important part of the stabilization phase. Once the patient achieves a stable dosing
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regimen and lack of continued cravings for opiate abuse the maintenance phase begins.
During this phase the patient is maintained on their steady dose. The length of this phase
is contingent upon patient performance and comfort, and also the judgment of the
clinician. During the maintenance phase doses can continue to be adjusted and
psychosocial and behavioral interventions are also often continued.

Extended release naltrexone – a new medication-assisted treatment
Naltrexone is a long-acting, full opioid-receptor antagonist utilized primarily in the
treatment of alcohol and opioid dependence. Recent data [70] has shown a depot
formulation of naltrexone as an effective treamtment modality for prevention of relapse
in substance-dependent patients who have already undergone detoxification. Recently,
Vivitrol, a depot, extended-release formulation of naltrexone, was approved in the United
States for the treatment of opioid dependence; similar to buprenorphine, utilization of
Vivitrol must follow detoxification from opioids.
Given naltrexone‟s pure opioid antagonist properties there are no regulatory barriers to
offering treatment. Additionally, the depot formulation comes in a monthly dosage.
Given these properties, there is hope that Vivitrol may further expand access to
medication-assisted treatments in patients previously unable to access resources due to
the regulations and challenges surrounding methadone and buprenorphine.

Tuberculosis screening in buprenorphine treatment programs
Despite significant increases in access to medication-assisted treamtment over the last 40
years, there remains significant stigma, regulatory barriers, and limited funding for such
treatments. While the overall number of patients receiving treatment has increased,
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currently in the United States, only 15–20% of opioid-dependent patients have access to
maintenance treatment [71, 72]. It is estimated that only approximately 200,000 patients
have access to methadone [73], while in 2009 only approximately 600,000 patients had
access to buprenorphine1.[74]. Currently depot naltrexone is too new to accurately
estimate the number of patients on treatment.
Given the great gap in medication-assisted treatment available to this population, there is
a significant need for increased drug treatment opportunities. In parallel, given the
marginalization of this population from mainstream health care services, there is also
need for enhanced primary care mechanisms to treat the medical co-morbidities of this
population. By creating innovative strategies to treat substance dependence in a primary
care setting public health practitioners have already expanded opportunities for these
patients [25, 27, 68, 75, 76]. Further expansion of substance abuse treatment programs
integrated with primary care services can address both the continued disparity in drug
treatment as well as medical care available to this population [5].
Some treatment programs have begun to respond to this need by integrating primary care
services with substance abuse treatment [23, 25, 27, 77-79]. These programs include
screening and treatment of diseases commonly affecting substance users as well as
induction and stabilization on medication-assisted treatments such as methadone and

1

As of writing there are 20,180 buprenorphine-certified physicians in the United States. While no
definitive numbers are yet available describing exactly how many patients have received/are receiving
buprenorphine we know that during the 2009 year 640,000 individuals received a Suboxone/Subutex
prescription, however length and number of refills of these prescriptions varied significantly. Through
personal communication with Dr. Douglas Bruce of Yale University only “half or less [of these] are in
„active treatment‟.”
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buprenorphine [27, 44, 80-82]. Further, such programs are situated and conducted in
ways more amenable to the specific needs of this population [5, 27].
As previously discussed, a key component of health services for this population must
address the increased prevalence of infectious diseases such as tuberculosis, HIV and
viral hepatitis. In examining these programs with an eye towards tuberculosis control,
methadone maintenance treatment programs in particular have successfully incorporated
tuberculosis screening. Additionally, these programs also include further linkage to
directly observed preventive therapy for those requiring tuberculosis treatment [81-84].
Methadone treatment guidelines in the United States, as well as recommendations from
the World Health Organization and Center for Disease Control and Prevention support
the continued usage of such programs as evidence-based and cost-effective [51, 82]
means of detecting and treating tuberculosis among opioid-dependent patients [85, 86].
Because of buprenorphine‟s liberalized regulatory framework and its consequent
availability to the primary-care practitioner, buprenorphine maintenance treatment has the
potential to greatly increase the availability of opiate-replacement therapy to those
currently without access. Further, if substance abuse treatment is coupled with primary
care services, such expansion into the primary care setting also has the dual benefit of
enhancing access for this population to ancillary services such as tuberculosis screening
[87]. Regulations for methadone treatment programs, including recommendations for
ancillary services offered, are well-founded after over 40 years of use in the clinical
setting. However, as standards of care for buprenorphine treatment continue to evolve,
policy recommendations for associated clinical services, such as tuberculosis screening
via tuberculosis skin testing, do not yet exist, nor is there data to support or refute such
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policies. Further, such programs are important to enhance treatment of both latent and
active tuberculosis in this patient population and inform the development of further
linkages to care for both isoniazid preventive therapies – for latent tuberculosis – as well
as treatment programs for active infections including directly observed therapy programs.
For this reason, we have examined the need and feasibility for implementation of a
tuberculosis screening program in the setting of a buprenorphine treatment program.
This research compares the prevalence of tuberculosis skin testing positivity among
matched clients contemporaneously enrolled in buprenorphine and methadone treatment
programs within inner-city New Haven, Connecticut. The treatment program described is
the first mobile, community-based model for buprenorphine treatment and will also be
discussed [88].

Statement of Purpose
While buprenorphine has been studied since the 1970s, strategies for optimizing
buprenorphine maintenance treatment programs to provide associated primary care
services for this population continue to be assessed and revised. This study will address
the particular issue of tuberculosis screening in buprenorphine treatment programs.
While the correlation between opiate addiction and tuberculosis infection has been well
documented, and there are established international guidelines for tuberculosis screening
in methadone programs, there has been to date no published investigation on the
feasibility and efficacy of tuberculosis screening incorporated into buprenorphine
programs. Using the cohort of buprenorphine treatment patients here described, this
study will compare positive rates of tuberculin skin testing to a contemporaneous and
geographically similar matched cohort of methadone maintenance treatment patients.
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Cohort averages as well as sub-group analysis will be described. Implications for the
need and practicality of such tuberculosis screening in buprenorphine maintenance
treatment programs will be discussed.

Hypotheses
1. The prevalence of positive tuberculin skin tests in a buprenorphine treatment
program will be similar to a contemporaneous and matched cohort of methadone
treatment patients.
2. It is possible to provide effective tuberculosis screening in the setting of a
buprenorphine treatment program

Aims of Research
1. To evaluate the prevalence of positive tuberculin skin tests in contemporaneous,
matched cohorts of buprenorphine and methadone maintenance treatment patients
2. To assess the feasibility of implementing a tuberculosis screening program in a
buprenorphine maintenance treatment program

Methods
Study Design
A cross-sectional analysis of a retrospective cohort study was conducted to compare the
prevalence of tuberculin skin test positivity between patients enrolled in the country‟s
first mobile, community-based buprenorphine stabilization and induction program to
contemporaneous patients enrolled in a nearby methadone maintenance treatment
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program. Both treatment-derived study groups were from the city of New Haven,
Connecticut and were matched across four criteria.

Ethical approval
This study was approved through the Yale University School of Medicine‟s Human
Investigation Committee (HIC# 27630).

Site Descriptions
New Haven, Connecticut

New Haven is a moderate-sized, post-industrial, city of approximately 130,000 with a
wide socioeconomic diversity. Yale University is located in New Haven, however New
Haven is also home to significant populations of African American and Latino American
populations. The “town-gown” relations between the former and latter are stark and
socioeconomic, political and health inequities are significant. Unemployment and
poverty, substance abuse (including a high degree of injecting drug use), HIV and mental
illness have made a deep impact upon the city.
Community Health Care Van

The Community Health Care Van (CHCV) is a 36-foot mobile medical facility that
provides health services in parallel to a needle-exchange program in New Haven,
Connecticut. The CHCV provides health services five days per week throughout four
neighborhoods in the New Haven area. While some areas of New Haven are quite
affluent, the neighborhoods the CHCV serves are disproportionately affected by poverty,
substance abuse, HIV, Hepatitis C, and mental illness. The CHCV provides a variety of
basic treatment and preventive health services including basic medical care (as provided
by a nurse practitioner/physician‟s assistant), screening for sexually transmitted
infections, tuberculosis, and HIV, directly observed HIV therapy, referral to drug
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treatment facilities and case management services, and buprenorphine induction and
stabilization treatment for opioid-dependent patients. The CHCV operates with the
express goal of offering health services to marginalized populations within the New
Haven area in a manner which enables patients to effectively access these services. The
focus of this research is in particular on the CHCV‟s provision of buprenorphine
induction and stabilization services and the concurrent screening for tuberculosis in this
population [44, 89].
The CHCV was first developed in 1991 when it operated out of an 18-foot van and
provided services only one day per week. Services expanded to two days per week in
1994, offering HIV counseling and testing, social work referrals and acute medical care.
The van expanded to its current form in 1996 and now has two examination rooms and
one counseling room. Service provision has been continually expanded both in scope and
in number of days offered since 1996. Clinical care and medications donated through
affiliated programs are provided free of charge to uninsured patients and all patients are
offered referral services to local and regional health facilities as indicated [88, 89]. The
clientele of the CHCV are diverse yet all from particularly disadvantaged and
underserved backgrounds. Over 35% are previous or current injecting drug users,
approximately 70% are unemployed, 27% reported previous or current commercial sex
work, and 26% had been in jail or prison in the 6 months prior to CHCV engagement
[89].
Key components of the CHCV‟s buprenorphine treatment program include rapid
initiation of opioid-replacement therapy, surveillance for associated infectious diseases
and/or psychiatric co-morbidities, and street-level case management services. An
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additional critical component of the CHCV program is its harm reduction approach to
complicated patients with multiple health and psychosocial co-morbidities. With
particular regard to the buprenorphine treatment program, if patients are effectively
taking their buprenorphine and engaging in parallel psychosocial and behavioral
counseling, other high-risk behaviors such as continued illicit substance abuse (e.g. crack
cocaine) are tolerated and not addressed punitively (e.g. discharge from the
buprenorphine program or judgement/stigmatization from health care providers at the
CHCV). Such harm-reduction techniques have been well established as effective means
of treating substance abuse and retaining patients in active engagement with health
providers. This approach helps to maintain patients engaged in health services and
counseling creating an environment in which further behavioral modification and general
health improvement may occur [28].
While such an approach has proven effective in enhancing the provision of health
services to this marginalized population, it also entails certain challenges in
implementation. This patient population frequently has difficulty in maintaining set
appointments thus requiring significant flexibility in staffing and time allocation for
counseling sessions. The CHCV program was developed with the intention of ensuring
therapeutic encounters at the time the patient presented for treatment, in direct contrast to
the standard health care system which is centered on clinician-set appointments. This
operations model requires staff to be flexible to see patients that they have not previously
seen, at times they had not expected patients to arrive, yet also ensures patients are
engaged in health services in a manner that their challenging life circumstances can
accommodate. All staff accordingly are connected via cell phones and able to
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communicate with other counselors and health care providers and are additionally colocated within the same mobile unit to allow one staff member to assist another when
patients unexpectedly arrive and/or require more attention than typically expected.
Providing health services in this fashion is time-intensive and costly, however by
adopting a harm-reduction approach the CHCV has effectively provided health services
to a population previously marginalized from the health care system and ultimately
enhanced the health status of this population [27, 44, 89].
Buprenorphine Maintenance Treatment Subjects

Buprenorphine treatment subjects were derived from Project BEST – Buprenorphine
Entry into Substance abuse Treatment – which is the first mobile, community-based,
buprenorphine induction and stabilization program in the United States [44]. Project
BEST operates out of the CHCV as described above and is funded by the Substance
Abuse and Mental Health Services Agency (SAMHSA). All patients enrolling in Project
BEST underwent induction and treatment in accordance with Treatment Improvement
Protocol 40 guide-lines [90].
Criteria for inclusion in buprenorphine treatment included:
1.
2.
3.
4.

fulfilling DSM-IV criteria for opioid dependence;
no previous uncontrolled benzodiazepine abuse;
hepatic transaminase values less than five times the upper limit of normal; and
a negative pregnancy test for women of child-bearing age.

Induction to Project BEST consisted of a standardized protocol over a two-day period.
On the first day patients received 8mg divided into two doses over 1 to 2 hours, and
16mg on the second day. In addition to buprenorphine patients also received evidencebased drug treatment counseling. Manualized counseling included an initial four weeks
of motivational enhancement therapy and an additional eight weeks of cognitive
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behavioral therapy [91]. Patients enrolled in the program also received weekly urine
immunoassay tests for opiates, cocaine, THC, methadone and/or benzodiazepines.
Following the initial 12 weeks of treatment patients returned for urine toxicology and
counseling at a frequency determined by the clinician, per the patient‟s perceived stability
and progress in the program [88].
Project BEST utilized a single pharmacy for all buprenorphine provision. Early in
treatment patients were prescribed only one-week supplies of buprenorphine which was
intended to last from one counseling appointment to the next. Prescriptions were written
for a one-week bottle with 3 refills however patients were required to show up to
counseling sessions in order to fill the refill. The latter was accomplished by never
providing patients with an actual prescription but instead a voucher. This voucher
required that both the patient and the counselor sign it at the time of the counseling
session, and also emboss it with a program seal. The pharmacy ensured that only
vouchers – and never prescriptions – that were doubly signed and embossed, were filled.
Through this mechanism Project BEST was able to ensure that all buprenorphine
treatment was accompanied by a minimum of 12 weeks counseling as patients began the
program [88].
In addition to buprenorphine maintenance treatment, all Project BEST enrollees are
routinely screened for HIV, tuberculosis, hepatitis B and C, and sexually transmitted
diseases [44, 92]. Hepatitis B vaccination is also provided for eligible participants [93].
All Project BEST participants also undergo health surveys to collect relevant information
about their past and current health status, substance abuse behavior, socioeconomic and
demographic information. These surveys include the Addiction Severity Index (ASI)
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[94], the Structured Clinical Interview for DSM-IV (SCID) [95], the CHCV Short and
Long forms, and the Project BEST Supplemental Survey [88], and are conducted at
induction as well as periodically thereafter. In addition to the surveys documented,
subjects enrolled in Project BEST provided informed consent to access all medical
records from one year prior to induction to five years following enrollment.
Methadone Maintenance Treatment Subjects

To investigate the concurrent prevalence of tuberculosis among methadone maintenance
patients in the area, characteristics from Project BEST participants were matched to
methadone patients enrolled at The APT Foundation in New Haven, Connecticut. The
APT Foundation (http://www.aptfoundation.org/) runs New Haven‟s largest (2,000
patients) methadone maintenance treatment program and has been providing treatment to
substance users for over 40 years. Through their methadone treatment program, all APT
Foundation clients are routinely screened for tuberculosis and mental illness. Additional
screening for hepatitis B and C is performed if deemed clinically appropriate, and HIV
testing is voluntary. Finally, all entrants to The APT Foundation‟s methadone
maintenance treatment program provide informed consent for medical chart review
extraction involving de-identified data.
Inclusion criteria for methadone maintenance treatment at The APT Foundation includes
1) adults over the age of 21 years old, 2) fulfillment of DSM-IV criteria for opiate
addiction of greater than one year in duration, and 3) one previous treatment failure.
Pregnant women under 21 years old are admitted on a case-by-case basis at the discretion
of clinicians. The APT Foundation serves a wide catchment area including cities
surrounding New Haven such as Milford, Old Saybrook and Wallingford [96].
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Definitions
In collecting data from Project BEST and The APT Foundation, medical record
formatting was distinct between the two groups, and therefore, reconciliation of selected
variables is required. The level of previous education was categorized differently in the
two study groups – for Project BEST patients, the number of months of education was
reported, with 144 months being equivalent to having completed a high-school education.
Conversely however, for APT Foundation patients education data was recorded only by
the number of years of education completed. Secondly, to assess the substance of abuse
preferred by each patient, data from both groups was compiled according to whether
patients had reported a given substance as their primary, secondary, or tertiary substance
of choice. Substances that were listed but not classified as primary, secondary, or
tertiary, were not included in data analysis. Last, to evaluate the psychiatric comorbidities of patients, including previous and current treatment histories, all enrollees
were defined to have an a priori diagnosis of substance abuse. Additional psychiatric comorbidities were defined if, in addition to their substance abuse treatment, patients were
also engaged in outpatient psychiatric care, with or without prescription medications,
prior to buprenorphine or methadone maintenance treatment enrollment. This psychiatric
outpatient data was reported through the Addiction Severity Index survey for Project
BEST clients and through a standardized admission form for all patients at The APT
Foundation.

Data Sources
Data for Project BEST buprenorphine and APT Foundation methadone maintenance
treatment subjects were compared for enrollees from January 1st, 2005 to June 30th, 2007.
Subjects from Project BEST were matched to clients at The APT Foundation on four
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criteria including age, gender, race, and previous history of crack or cocaine use.
Utilizing these criteria allowed for the evaluation of factors previously associated with
tuberculin skin test positivity [97, 98] in comparing patients in Project BEST
buprenorphine treatment to those in The APT Foundation‟s methadone program. Chart
review was performed by author RS on 190 patients from the buprenorphine and
methadone treatment matched groups using a uniform data extraction instrument. The
data extraction instrument was developed using the Teleform software package [99]
enabling hand-written chart-review data to be easily translated into Microsoft Excel
databases for analysis. Clinical data, including previous and enrollment tuberculin skin
test results, was extracted retrospectively via chart review in accordance with HIC
#27630. All data was subsequently uploaded to databases stored at The Yale AIDS
Program at 135 College St, Suite 323, where it was kept under password protection in
accordance with HIC #27630 protocol.
Tuberculin skin test results were unavailable for 15 subjects in the Project BEST cohort
and 19 in The APT Foundation cohort due to insufficient record keeping at the study
sites. These subjects were excluded from the final data analysis and are not exhibited in
the results tables. Ultimately data collection resulted in 175 and 171 subjects in the
Project BEST and The APT Foundation study groups, respectively. To account for the
missing tuberculin skin testing data, each group was reassessed. This re-evaluation
verified that characteristics set by the original matching criteria were retained. No
statistically significant differences were found in this re-evaluation.
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Data Analysis
The prevalence of tuberculin skin test positivity and comparison of demographic and
substance use characteristics were compared between buprenorphine and methadone
treatment study groups using two-sided chi-square tests (alpha = .05). Bivariate
associations with the primary outcome (tuberculin skin test positivity) were calculated to
determine variables that could be included into the final multiple logistic regression
model for predicting skin test positivity. The Akaike information criterion (AIC) was
used to assess model fit – a lower AIC value indicates a better balance of parsimony and
clarification of variance. A p-value <0.20 was used to enter and leave the regression
model. The two-sided Wald‟s test (alpha = .05) was used to assess significance of each
of the variables. All statistical analyses were performed at The Yale AIDS Program
using SAS, version 9.1.3 (SAS Institute, Cary, NC).

Results
The demographic and health characteristics of the two comparison groups, described in
Table 1, did not differ statistically. Though the two groups did not differ on the primary
outcome (9% in both groups were tuberculin skin test positive), the buprenorphine
treatment group contained twice as many (6% vs. 3%) “new” positive skin test results,
with the opposite found in the methadone treatment group where twice as many (6% vs.
3%) were “previously detected” positive skin tests. Thus, 10 (62.5%) of the 16
buprenorphine treatment subjects and 5 (33.3%) of the 15 methadone treatment subjects
had “new” positive skin test results and trended toward significance (p = .10).
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Though not significant, there was a trend toward higher levels of education in the
buprenorphine treatment group with 27% having completed education beyond high
school compared to 19% in the methadone treatment group (p =.07). Over a third of all
patients in both groups (36% of buprenorphine vs. 34% of methadone treatment) met
criteria for an Axis I disorder, thus qualifying as having a co-morbid mental illness in
addition to opioid-dependence.
There were, however, significant differences between the two groups in their reported
substance use preferences (Table 2). Enrollees in buprenorphine treatment were
statistically more likely to report secondary preferences for alcohol (30% vs. 8%, p <
.0001) and benzodiazepines (8% vs. 3%, p = .038) than their methadone treatment
counterparts, while the latter expressed higher preferences for heroin (91% vs. 71%, p <
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.0001) and cocaine (69% vs. 26%, p < .0001).

Unadjusted and adjusted analyses are presented in Table 3. Unadjusted analysis
illustrated a significant association between tuberculin skin test positivity and black race
(OR = 2.72). The adjusted analysis indicated statistically significant higher associations
between skin test positivity and blacks (AOR = 3.53, 95% CI = 1.28–9.77), Hispanics
(AOR = 3.11, 95% CI = 1.12–8.60) and higher education status (AOR = 3.01, CI = 1.20–
7.53). All other associations were non-significant.
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Discussion
The purpose of this study was to evaluate the prevalence of tuberculin skin test positivity
in a buprenorphine treatment group as compared to a similar and contemporaneous
methadone treatment cohort. Buprenorphine is a relatively new treatment modality for
opiate-dependent patients and accordingly best practices surrounding the implementation
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of such programs are not fully understood. Given the pre-existing guidelines that all
methadone treatment patients should be screened for tuberculosis, yet the lack of
evidence supporting or refuting similar guidelines for buprenorphine treatment programs,
the data from our study can be used to inform policy and the guidelines surrounding
substance abuse treatment programs.
To our knowledge, this is the first study examining the prevalence of tuberculin skin test
positivity in a group of patients receiving buprenorphine treatment. Data from this study
illustrate a similar prevalence of 9% in new enrollees in both methadone and
buprenorphine maintenance treatment programs in the same community. In light of the
current recommendations that all clients entering methadone treatment programs be
screened for tuberculosis, our findings suggest that similar screening practices are
warranted for patients initiating buprenorphine treatment.
In particular, such screening is important as buprenorphine may be reaching a different
target of opioid-dependent patients in community settings as evidenced in our study by
the differing poly-substance use profiles. Though not reaching statistical significance,
the trend that the buprenorphine program identified more “new” positive skin tests
requires further investigation, and again suggests that buprenorphine may be reaching a
group of opioid-dependent patients with different risk profiles. Data found in our study
suggesting differing characteristics between methadone and buprenorphine treatment
patients is consistent with previous research [77]. Nonetheless, irrespective of the
different sociodemographic and/or risk profiles highlighted by this and previous data,
similar prevalence of skin test positivity still suggests that buprenorphine enrollees also
require tuberculosis screening at entrance.
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Similar to previous studies, these findings additionally suggest higher positive
tuberculosis prevalence among racial and ethnic minorities – specifically blacks and
Hispanics [100]. Such results highlight the different health risks of people of color in the
United States and confirm not only the need for identifying those at highest risk for
tuberculosis, but ensuring that they are screened and prophylactically treated.
Paradoxically in this study, higher education, often a marker of higher socioeconomic
status, was associated with a positive tuberculin skin test. To our knowledge, this has not
been previously demonstrated among treatment-seeking opioid-dependent populations.
A potential explanation of this result is that those with higher levels of education who
were skin test positive were those that had formerly worked within congregate settings,
such as nursing homes, hospitals or even prisons, where tuberculin skin test conversions
would be expected. An alternative explanation of these data could be that those
Hispanics with higher education were not U.S.-born, but came to the United States in
search of financial opportunities and had been previously exposed to tuberculosis within
their home or endemic within their country. Given a higher previous educational history
we could conjecture that such persons were more able to immigrate to the United States
in search of more gainful employment opportunities. We assessed the latter relationship,
however, and there was no significant interaction. Further studies are warranted to more
accurately characterize this population, to confirm or refute our findings, and to better
establish the relationship between higher education and tuberculin skin test positivity.
Of note, our study offers implications for the development of enhanced linkages to
tuberculosis treatment strategies for the buprenorphine patient population. Previously it
has been shown that isoniazid treatment offered in parallel to methadone maintenance
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therapy programs is both effective [101] and cost-effective [102], with innovative
treatment models enhancing adherence [103, 104]. In part, this is due to the increased
structured environment that methadone treatment programs offer with consistent and
regular follow-up enabling parallel directly observed isoniazid therapy. However, in
contrast, due to the more rapid rate at which buprenorphine maintenance treatment
patients receive at-home medication privileges, such consistent structure is typically not
available. Thus, in parallel to implementing screening programs for tuberculosis with
buprenorphine maintenance treatment, consideration should also be paid to alternative
interventions to ensure adequate treatment success on tuberculosis treatment. Previous
strategies to enhance adherence [103, 104] may be instructive yet further research will be
required to optimize treatment success. Notably, our data also offers potential
implications in the international arena. While medication-assisted treatments are limited,
if not non-existent, in many countries outside of the United States, increasingly other
nations are developing substance-dependence treatment programs utilizing medicationassisted therapies. Data from developed country models such as the long-standing
programs in the UK [105] have offered critical insight on the development of newer
programs in countries such as Malaysia or the Ukraine. Both of the latter examples have
significant HIV epidemics largely fueled by injecting drug use, and therefore the
implementation of safe, effective and cost-effective substance-dependence programs will
be critical to their public health systems [106, 107]. Our data offers an important insight
for such programs, especially those in which medication-assisted treatment will address
large burdens of HIV and associated conditions such as tuberculosis. Further data from
studies such as our own will help to inform these best-practices and thereby enhance the
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evidence base for developing programs. By adopting tuberculosis screening in parallel
with the implementation of methadone and/or buprenorphine maintenance treatment
programs, public health investments in newly developing programs will be more effective
and cost-effective.
Notably, this study has several important limitations. The sample size of the
buprenorphine treatment program, while growing, remains relatively small. Furthermore,
recommendations stemming from these data are specific to the New Haven community
context, and given the paucity of existing buprenorphine treatment programs, it is as yet
unclear to what extent our data are generalizeable to the larger opioid-dependent patient
population. Additionally, the CHCV is a particular buprenorphine setting that may further
limit the degree of generalizability of our data. Finally, with particular regard to analysis
of psychiatric co-morbidities, we recognize survey data as utilized in this study are less
reliable than validated diagnostic indices. As a result, we suspect that we have likely
underestimated the overall burden of psychopathology in our study groups.
Despite these limitations, these data provide preliminary but compelling support for
incorporating tuberculosis screening into buprenorphine treatment programs. Such
inclusion provides increased potential for detection of latent tuberculosis and enhances
access to onsite primary care services for an already marginalized patient population.
Increased detection of latent tuberculosis may, therefore, result in increased access to
treatment due to engagement in continuity of care. This is particularly true because of
buprenorphine‟s availability within the primary care setting where regular tuberculin skin
test screening would facilitate linkage to treatment. Finally, our experience
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implementing this screening program has illustrated that it is a practical model that can be
considered for other buprenorphine treatment programs.
As research continues to define standards of care for buprenorphine maintenance
treatment, other mechanisms to ensure increased access to primary care services for
opioid-dependent patients, in particular targeting those co-morbidities known to exist in
this population, should remain a priority.
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